Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 203

1.

MDM2-TP53 Crossregulation: An Underestimated Target to Promote Loss of TP53 Function and Cell Survival.

Soussi T, Kroemer G.

Trends Cancer. 2018 Sep;4(9):602-605. doi: 10.1016/j.trecan.2018.07.001. Epub 2018 Jul 21.

PMID:
30149877
2.

Seshat: A Web service for accurate annotation, validation, and analysis of TP53 variants generated by conventional and next-generation sequencing.

Tikkanen T, Leroy B, Fournier JL, Risques RA, Malcikova J, Soussi T.

Hum Mutat. 2018 Jul;39(7):925-933. doi: 10.1002/humu.23543. Epub 2018 May 17.

PMID:
29696732
3.

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.

Malcikova J, Tausch E, Rossi D, Sutton LA, Soussi T, Zenz T, Kater AP, Niemann CU, Gonzalez D, Davi F, Gonzalez Diaz M, Moreno C, Gaidano G, Stamatopoulos K, Rosenquist R, Stilgenbauer S, Ghia P, Pospisilova S; European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) — TP53 network.

Leukemia. 2018 May;32(5):1070-1080. doi: 10.1038/s41375-017-0007-7. Epub 2018 Feb 2. Review.

4.

Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide.

Lodé L, Ménard A, Flet L, Richebourg S, Loirat M, Eveillard M, Le Bris Y, Godon C, Theisen O, Gagez AL, Cartron G, Commes-Maerten T, Villemagne B, Luycx O, Godmer P, Pellat-Deceunynck C, Soussi T, Béné MC, Delaunay J, Peterlin P.

Haematologica. 2018 Apr;103(4):e143-e146. doi: 10.3324/haematol.2017.181404. Epub 2017 Dec 21. No abstract available.

5.

Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple TP53 alterations.

Lodé L, Ameur A, Coste T, Ménard A, Richebourg S, Gaillard JB, Le Bris Y, Béné MC, Lavabre-Bertrand T, Soussi T.

Haematologica. 2018 Jan;103(1):e13-e16. doi: 10.3324/haematol.2017.176719. Epub 2017 Oct 27. No abstract available.

6.

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T.

Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Review.

7.

Synonymous Somatic Variants in Human Cancer Are Not Infamous: A Plea for Full Disclosure in Databases and Publications.

Soussi T, Taschner PE, Samuels Y.

Hum Mutat. 2017 Apr;38(4):339-342. doi: 10.1002/humu.23163. Epub 2017 Feb 2.

PMID:
28026089
8.

TP53 and 53BP1 Reunited.

Soussi T, Kroemer G.

Trends Cell Biol. 2017 May;27(5):311-313. doi: 10.1016/j.tcb.2016.10.004. Epub 2016 Nov 17.

PMID:
27866833
9.

TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes.

Lazarian G, Tausch E, Eclache V, Sebaa A, Bianchi V, Letestu R, Collon JF, Lefebvre V, Gardano L, Varin-Blank N, Soussi T, Stilgenbauer S, Cymbalista F, Baran-Marszak F.

Int J Cancer. 2016 Oct 15;139(8):1759-63. doi: 10.1002/ijc.30222. Epub 2016 Jun 24.

10.

Genetic profiling of CLL: a 'TP53 addict' perspective.

Lodé L, Cymbalista F, Soussi T.

Cell Death Dis. 2016 Jan 14;7:e2042. doi: 10.1038/cddis.2015.415. No abstract available.

11.

TP53: an oncogene in disguise.

Soussi T, Wiman KG.

Cell Death Differ. 2015 Aug;22(8):1239-49. doi: 10.1038/cdd.2015.53. Epub 2015 May 29. Review.

12.

The TP53 gene network in a postgenomic era.

Soussi T.

Hum Mutat. 2014 Jun;35(6):641-2. Review.

PMID:
24753184
13.

Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era.

Soussi T, Leroy B, Taschner PE.

Hum Mutat. 2014 Jun;35(6):766-78. doi: 10.1002/humu.22561. Epub 2014 May 6. Review.

PMID:
24729566
14.

Analysis of TP53 mutation status in human cancer cell lines: a reassessment.

Leroy B, Girard L, Hollestelle A, Minna JD, Gazdar AF, Soussi T.

Hum Mutat. 2014 Jun;35(6):756-65. doi: 10.1002/humu.22556. Epub 2014 May 6. Review.

15.

TP53 mutations in human cancer: database reassessment and prospects for the next decade.

Leroy B, Anderson M, Soussi T.

Hum Mutat. 2014 Jun;35(6):672-88. doi: 10.1002/humu.22552. Review.

PMID:
24665023
16.

Locus-specific databases in cancer: what future in a post-genomic era? The TP53 LSDB paradigm.

Soussi T.

Hum Mutat. 2014 Jun;35(6):643-53. doi: 10.1002/humu.22518. Epub 2014 Mar 5. Review.

PMID:
24478183
17.

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis.

Leroy B, Fournier JL, Ishioka C, Monti P, Inga A, Fronza G, Soussi T.

Nucleic Acids Res. 2013 Jan;41(Database issue):D962-9. doi: 10.1093/nar/gks1033. Epub 2012 Nov 17.

18.

Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors.

Edlund K, Larsson O, Ameur A, Bunikis I, Gyllensten U, Leroy B, Sundström M, Micke P, Botling J, Soussi T.

Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9551-6. doi: 10.1073/pnas.1200019109. Epub 2012 May 24.

19.

Advances in carcinogenesis: a historical perspective from observational studies to tumor genome sequencing and TP53 mutation spectrum analysis.

Soussi T.

Biochim Biophys Acta. 2011 Dec;1816(2):199-208. doi: 10.1016/j.bbcan.2011.07.003. Epub 2011 Jul 23. Review.

PMID:
21791238
20.

TP53 mutations in human cancer: database reassessment and prospects for the next decade.

Soussi T.

Adv Cancer Res. 2011;110:107-39. doi: 10.1016/B978-0-12-386469-7.00005-0. Review.

PMID:
21704230
21.

The history of p53. A perfect example of the drawbacks of scientific paradigms.

Soussi T.

EMBO Rep. 2010 Nov;11(11):822-6. doi: 10.1038/embor.2010.159. Epub 2010 Oct 8. No abstract available.

22.

TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations.

Zenz T, Vollmer D, Trbusek M, Smardova J, Benner A, Soussi T, Helfrich H, Heuberger M, Hoth P, Fuge M, Denzel T, Häbe S, Malcikova J, Kuglik P, Truong S, Patten N, Wu L, Oscier D, Ibbotson R, Gardiner A, Tracy I, Lin K, Pettitt A, Pospisilova S, Mayer J, Hallek M, Döhner H, Stilgenbauer S; European Research Initiative on CLL (ERIC).

Leukemia. 2010 Dec;24(12):2072-9. doi: 10.1038/leu.2010.208. Epub 2010 Sep 23.

PMID:
20861914
23.

Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.

Lodé L, Eveillard M, Trichet V, Soussi T, Wuillème S, Richebourg S, Magrangeas F, Ifrah N, Campion L, Traullé C, Guilhot F, Caillot D, Marit G, Mathiot C, Facon T, Attal M, Harousseau JL, Moreau P, Minvielle S, Avet-Loiseau H.

Haematologica. 2010 Nov;95(11):1973-6. doi: 10.3324/haematol.2010.023697. Epub 2010 Jul 15.

24.

MUT-TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancer.

Soussi T, Hamroun D, Hjortsberg L, Rubio-Nevado JM, Fournier JL, Béroud C.

Hum Mutat. 2010 Sep;31(9):1020-5. doi: 10.1002/humu.21313.

PMID:
20572016
25.

Investigation and prediction of the severity of p53 mutants using parameters from structural calculations.

Carlsson J, Soussi T, Persson B.

FEBS J. 2009 Aug;276(15):4142-55. doi: 10.1111/j.1742-4658.2009.07124.x. Epub 2009 Jun 25.

26.

When mutant p53 plays hide and seek: a new challenge for diagnosis and therapy?

Soussi T, Hjortsberg L.

Trends Mol Med. 2009 Jan;15(1):1-4. doi: 10.1016/j.molmed.2008.11.002. Epub 2008 Dec 25.

PMID:
19097939
27.

Mutant p53 protein localized in the cytoplasm inhibits autophagy.

Morselli E, Tasdemir E, Maiuri MC, Galluzzi L, Kepp O, Criollo A, Vicencio JM, Soussi T, Kroemer G.

Cell Cycle. 2008 Oct;7(19):3056-61. Epub 2008 Oct 6. Erratum in: Cell Cycle. 2014;13(14):2311.

PMID:
18818522
28.

Breast-cancer stromal cells with TP53 mutations.

Zander CS, Soussi T.

N Engl J Med. 2008 Apr 10;358(15):1635; author reply 1636. No abstract available.

PMID:
18411430
29.

Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination.

Berglind H, Pawitan Y, Kato S, Ishioka C, Soussi T.

Cancer Biol Ther. 2008 May;7(5):699-708. Epub 2008 May 11.

PMID:
18277095
30.

Shaping genetic alterations in human cancer: the p53 mutation paradigm.

Soussi T, Wiman KG.

Cancer Cell. 2007 Oct;12(4):303-12. Review.

31.

Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors.

Ren ZP, Olofsson T, Qu M, Hesselager G, Soussi T, Kalimo H, Smits A, Nistér M.

J Neuropathol Exp Neurol. 2007 Oct;66(10):944-54.

PMID:
17917588
32.

p53 alterations in human cancer: more questions than answers.

Soussi T.

Oncogene. 2007 Apr 2;26(15):2145-56. Review.

PMID:
17401423
33.

MUT-TP53: a versatile matrix for TP53 mutation verification and publication.

Soussi T, Rubio-Nevado JM, Ishioka C.

Hum Mutat. 2006 Nov;27(11):1151-4. No abstract available.

PMID:
16941637
34.

Megaloblastic anemia in North Africa.

Maktouf C, Bchir A, Louzir H, Mdhaffer M, Elloumi M, Ben Abid H, Meddeb B, Makni F, Laatiri A, Soussi T, Hafsia A, Dellagi K.

Haematologica. 2006 Jul;91(7):990-1. Epub 2006 Jun 1.

35.

Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study.

Iacopetta B, Russo A, Bazan V, Dardanoni G, Gebbia N, Soussi T, Kerr D, Elsaleh H, Soong R, Kandioler D, Janschek E, Kappel S, Lung M, Leung CS, Ko JM, Yuen S, Ho J, Leung SY, Crapez E, Duffour J, Ychou M, Leahy DT, O'Donoghue DP, Agnese V, Cascio S, Di Fede G, Chieco-Bianchi L, Bertorelle R, Belluco C, Giaretti W, Castagnola P, Ricevuto E, Ficorella C, Bosari S, Arizzi CD, Miyaki M, Onda M, Kampman E, Diergaarde B, Royds J, Lothe RA, Diep CB, Meling GI, Ostrowski J, Trzeciak L, Guzinska-Ustymowicz K, Zalewski B, Capellá GM, Moreno V, Peinado MA, Lönnroth C, Lundholm K, Sun XF, Jansson A, Bouzourene H, Hsieh LL, Tang R, Smith DR, Allen-Mersh TG, Khan ZA, Shorthouse AJ, Silverman ML, Kato S, Ishioka C; TP53-CRC Collaborative Group.

Ann Oncol. 2006 May;17(5):842-7. Epub 2006 Mar 8.

PMID:
16524972
36.

Locus-specific mutation databases: pitfalls and good practice based on the p53 experience.

Soussi T, Ishioka C, Claustres M, Béroud C.

Nat Rev Cancer. 2006 Jan;6(1):83-90. Review.

PMID:
16397528
37.

Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection.

Soussi T, Asselain B, Hamroun D, Kato S, Ishioka C, Claustres M, Béroud C.

Clin Cancer Res. 2006 Jan 1;12(1):62-9.

38.

The UMD TP53 database and website: update and revisions.

Hamroun D, Kato S, Ishioka C, Claustres M, Béroud C, Soussi T.

Hum Mutat. 2006 Jan;27(1):14-20.

PMID:
16278824
39.

The p53 pathway and human cancer.

Soussi T.

Br J Surg. 2005 Nov;92(11):1331-2. No abstract available.

PMID:
16240283
40.

The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.

Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N; TP53-CRC Collaborative Study Group.

J Clin Oncol. 2005 Oct 20;23(30):7518-28. Epub 2005 Sep 19. Review.

PMID:
16172461
41.

UMD (Universal Mutation Database): 2005 update.

Béroud C, Hamroun D, Collod-Béroud G, Boileau C, Soussi T, Claustres M.

Hum Mutat. 2005 Sep;26(3):184-91.

PMID:
16086365
42.

p53 mutation heterogeneity in cancer.

Soussi T, Lozano G.

Biochem Biophys Res Commun. 2005 Jun 10;331(3):834-42. Review.

PMID:
15865939
43.

A new set of monoclonal antibodies directed to proline-rich and central regions of p53.

Voeltzel T, Morel AP, Rostan MC, Ji J, Chiodino C, Ponchel F, Vigouroux J, Caron de Fromentel C, Soussi T, Ozturk M.

Hybrid Hybridomics. 2004 Oct;23(5):287-92.

PMID:
15672606
44.
45.

Quantitative fish determination of chromosome 3 arm imbalances in lung tumors by automated image cytometry.

Truong K, Gibaud A, Zalcman G, Guilly MN, Antoine M, Commo F, Fouquet C, Cadranel J, Soussi T, Dutrillaux B, Malfoy B.

Med Sci Monit. 2004 Nov;10(11):BR426-32. Epub 2004 Oct 26.

PMID:
15507848
46.

Harmonized microarray/mutation scanning analysis of TP53 mutations in undissected colorectal tumors.

Favis R, Huang J, Gerry NP, Culliford A, Paty P, Soussi T, Barany F.

Hum Mutat. 2004 Jul;24(1):63-75.

PMID:
15221790
47.

Versatile analysis of multiple macromolecular interactions by SPR imaging: application to p53 and DNA interaction.

Maillart E, Brengel-Pesce K, Capela D, Roget A, Livache T, Canva M, Levy Y, Soussi T.

Oncogene. 2004 Jul 15;23(32):5543-50.

PMID:
15184889
48.

Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study.

Fouquet C, Antoine M, Tisserand P, Favis R, Wislez M, Commo F, Rabbe N, Carette MF, Milleron B, Barany F, Cadranel J, Zalcman G, Soussi T.

Clin Cancer Res. 2004 May 15;10(10):3479-89. Erratum in: Clin Cancer Res. 2004 Aug 1;10(15):5295.

49.

Lack of HIN-1 methylation defines specific breast tumor subtypes including medullary carcinoma of the breast and BRCA1-linked tumors.

Tisserand P, Fouquet C, Barrois M, Gallou C, Dendale R, Stoppa-Lyonnet D, Sastre-Garau X, Fourquet A, Soussi T.

Cancer Biol Ther. 2003 Sep-Oct;2(5):559-63.

PMID:
14614327
50.

Supplemental Content

Loading ...
Support Center